Open AccessPsychosis Following Anti-Obesity Treatment with Rimonabant
Author(s) -
Tarik Ugur,
Marius Bartels,
Bernhard Kis,
Norbert Scherbaum
Publication year - 2008
Publication title -
obesity facts
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.398
H-Index - 45
eISSN - 1662-4033
pISSN - 1662-4025
DOI - 10.1159/000122763
Subject(s) - rimonabant , quetiapine , medicine , ziprasidone , schizophrenia (object oriented programming) , discontinuation , psychosis , anxiety , psychiatry , antipsychotic , depression (economics) , atypical antipsychotic , antagonist , cannabinoid receptor , macroeconomics , receptor , economics
In this report, we present the case of a patient with a relapse of schizophrenia following an episode of depression and increased anxiety after antiobesity treatment with rimonabant, a cannabinoid type 1 receptor antagonist.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom